You are here

  • Home
  • Archive
  • Volume 52, Issue 12
  • Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy

Article metrics

Article menu
Phenotypes
Original article
Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy

 

Online download statistics by month:

Online download statistics by month: October 2015 to March 2024

AbstractFullPdf
Oct 2015623027
Nov 201513111681
Dec 20152199467
Jan 20161278773
Feb 20161262625
Mar 2016543645
Apr 2016264429
May 2016322015
Jun 2016382655
Jul 2016211910
Aug 2016271916
Sep 2016322020
Oct 2016263018
Nov 2016291611
Dec 201624147
Jan 201725128
Feb 2017164
Mar 20170269
Apr 201704012
May 20170329
Jun 20178238
Jul 201727279
Aug 201737355
Sep 201748445
Oct 2017474711
Nov 201733298
Dec 201723238
Jan 2018312911
Feb 201828229
Mar 201829264
Apr 201830282
May 2018383910
Jun 2018373714
Jul 201834344
Aug 201856565
Sep 201868687
Oct 2018585811
Nov 201877773
Dec 201884808
Jan 201984809
Feb 201973735
Mar 2019413813
Apr 2019242016
May 201916166
Jun 2019171515
Jul 2019201613
Aug 201915911
Sep 201911108
Oct 201911117
Nov 2019161610
Dec 201926174
Jan 202023228
Feb 2020313011
Mar 202045447
Apr 2020202011
May 2020444316
Jun 202045448
Jul 202034358
Aug 202038308
Sep 2020454325
Oct 202028199
Nov 2020322315
Dec 2020343211
Jan 202131316
Feb 202121219
Mar 202126243
Apr 202124214
May 2021423813
Jun 2021565426
Jul 2021414117
Aug 2021302924
Sep 2021434120
Oct 2021343232
Nov 2021262519
Dec 2021393517
Jan 202218179
Feb 2022303010
Mar 2022312611
Apr 2022242215
May 2022393916
Jun 2022423615
Jul 202223217
Aug 2022424011
Sep 2022383522
Oct 202237376
Nov 2022423811
Dec 2022352510
Jan 202340308
Feb 202356529
Mar 2023504121
Apr 2023241512
May 2023292510
Jun 202341392
Jul 2023181814
Aug 2023433113
Sep 202321196
Oct 202346459
Nov 202384827
Dec 2023848010
Jan 202457457318
Feb 20242542527
Mar 20244032172
Total478442931588